Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives
Objective: To determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision. Methods: Global representatives attending the STI Vaccines: Opportunities for Research, Development, and Implementation symposiu...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Vaccine: X |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136221000243 |
id |
doaj-f24da7ec3884430eaa589dbd37d698b4 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kara M. Plotnikoff Robine Donken Laurie Smith Caroline Cameron D. Scott LaMontagne Julie A. Bettinger Manish Sadarangani Troy Grennan C. Sarai Racey Kevin Hybiske Monika Naus Amanda Monteiro Gina S. Ogilvie |
spellingShingle |
Kara M. Plotnikoff Robine Donken Laurie Smith Caroline Cameron D. Scott LaMontagne Julie A. Bettinger Manish Sadarangani Troy Grennan C. Sarai Racey Kevin Hybiske Monika Naus Amanda Monteiro Gina S. Ogilvie Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives Vaccine: X Sexually transmitted infections Prevention Vaccines Public health Priorities |
author_facet |
Kara M. Plotnikoff Robine Donken Laurie Smith Caroline Cameron D. Scott LaMontagne Julie A. Bettinger Manish Sadarangani Troy Grennan C. Sarai Racey Kevin Hybiske Monika Naus Amanda Monteiro Gina S. Ogilvie |
author_sort |
Kara M. Plotnikoff |
title |
Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives |
title_short |
Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives |
title_full |
Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives |
title_fullStr |
Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives |
title_full_unstemmed |
Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives |
title_sort |
priorities for sexually transmitted infection vaccine research and development: results from a survey of global leaders and representatives |
publisher |
Elsevier |
series |
Vaccine: X |
issn |
2590-1362 |
publishDate |
2021-08-01 |
description |
Objective: To determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision. Methods: Global representatives attending the STI Vaccines: Opportunities for Research, Development, and Implementation symposium preceding the STI & HIV World Congress in 2019 were invited to complete an electronic survey. We asked participants to rank items by importance/priority for STI vaccine development for the following areas of focus: specific STIs (gonorrhea, chlamydia, syphilis, herpes, and trichomoniasis), broad research domains (basic science, funding, communication, program planning, and vaccine hesitancy), and specific research activities related to these domains. We calculated weighted value scores based on the ranking (e.g., first, second, third) and the total number of responses in order to produce a ranked list of the priorities. Results: A total of 46 out of 97 (44%) symposium attendees responded to the survey. Gonorrhea was identified as the STI that should be prioritized for vaccine development, followed by syphilis with weighted value scores of 3.82 and 3.37, respectively, out of a maximum of five. Basic science (and vaccine development) was the domain ranked with the highest priority with a weighted value score of 4.78 out of six. Research activities related to basic science and vaccine development (including pre-clinical and clinical trials, and surveillance measures) and increased funding opportunities were the most highly ranked activities in the “STI vaccine development” and “research domains and activities” categories. Conclusion: Global leaders in attendance at the STI Vaccines symposium prioritized continued scientific work in vaccine development and program planning. Gonorrhea was identified as the highest priority infection, followed by syphilis. |
topic |
Sexually transmitted infections Prevention Vaccines Public health Priorities |
url |
http://www.sciencedirect.com/science/article/pii/S2590136221000243 |
work_keys_str_mv |
AT karamplotnikoff prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT robinedonken prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT lauriesmith prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT carolinecameron prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT dscottlamontagne prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT julieabettinger prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT manishsadarangani prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT troygrennan prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT csarairacey prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT kevinhybiske prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT monikanaus prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT amandamonteiro prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives AT ginasogilvie prioritiesforsexuallytransmittedinfectionvaccineresearchanddevelopmentresultsfromasurveyofgloballeadersandrepresentatives |
_version_ |
1721219510234513408 |
spelling |
doaj-f24da7ec3884430eaa589dbd37d698b42021-08-06T04:22:38ZengElsevierVaccine: X2590-13622021-08-018100107Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representativesKara M. Plotnikoff0Robine Donken1Laurie Smith2Caroline Cameron3D. Scott LaMontagne4Julie A. Bettinger5Manish Sadarangani6Troy Grennan7C. Sarai Racey8Kevin Hybiske9Monika Naus10Amanda Monteiro11Gina S. Ogilvie12School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Women’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, CanadaSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Women’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, Canada; Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, BC, CanadaWomen’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, Canada; Cancer Control Research, BC Cancer, Vancouver, BC, CanadaDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USAPATH, Center for Vaccine Innovation & Access, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USAWomen’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, Canada; Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, BC, CanadaVaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, CanadaDivision of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada; British Columbia Centre for Disease Control, Vancouver, BC, CanadaSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Women’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, CanadaDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USASchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Centre for Disease Control, Vancouver, BC, CanadaWomen’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, CanadaSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Women’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, Vancouver, BC, Canada; British Columbia Centre for Disease Control, Vancouver, BC, Canada; Corresponding author at: Women’s Health Research Institute, British Columbia Women’s Hospital and Health Centre, 4500 Oak Street, Vancouver, BC V6H 3N1, Canada.Objective: To determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision. Methods: Global representatives attending the STI Vaccines: Opportunities for Research, Development, and Implementation symposium preceding the STI & HIV World Congress in 2019 were invited to complete an electronic survey. We asked participants to rank items by importance/priority for STI vaccine development for the following areas of focus: specific STIs (gonorrhea, chlamydia, syphilis, herpes, and trichomoniasis), broad research domains (basic science, funding, communication, program planning, and vaccine hesitancy), and specific research activities related to these domains. We calculated weighted value scores based on the ranking (e.g., first, second, third) and the total number of responses in order to produce a ranked list of the priorities. Results: A total of 46 out of 97 (44%) symposium attendees responded to the survey. Gonorrhea was identified as the STI that should be prioritized for vaccine development, followed by syphilis with weighted value scores of 3.82 and 3.37, respectively, out of a maximum of five. Basic science (and vaccine development) was the domain ranked with the highest priority with a weighted value score of 4.78 out of six. Research activities related to basic science and vaccine development (including pre-clinical and clinical trials, and surveillance measures) and increased funding opportunities were the most highly ranked activities in the “STI vaccine development” and “research domains and activities” categories. Conclusion: Global leaders in attendance at the STI Vaccines symposium prioritized continued scientific work in vaccine development and program planning. Gonorrhea was identified as the highest priority infection, followed by syphilis.http://www.sciencedirect.com/science/article/pii/S2590136221000243Sexually transmitted infectionsPreventionVaccinesPublic healthPriorities |